Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial.

We evaluated the effectiveness of a low-intensity, home-based physical activity program (Onco-Move) and a moderate- to high-intensity, combined supervised resistance and aerobic exercise program (OnTrack) versus usual care (UC) in maintaining or enhancing physical fitness, minimizing fatigue, enhancing health-related quality of life, and optimizing chemotherapy completion rates in patients undergoing adjuvant chemotherapy for breast cancer.
We randomly assigned patients who were scheduled to undergo adjuvant chemotherapy (N = 230) to Onco-Move, OnTrack, or UC. Performance-based and self-reported outcomes were assessed before random assignment, at the end of chemotherapy, and at the 6-month follow-up. We used generalized estimating equations to compare the groups over time.
Onco-Move and OnTrack resulted in less decline in cardiorespiratory fitness (P < .001), better physical functioning (P ≤ .001), less nausea and vomiting (P = .029 and .031, respectively) and less pain (P = .003 and .011, respectively) compared with UC. OnTrack also resulted in better outcomes for muscle strength (P = .002) and physical fatigue (P < .001). At the 6-month follow-up, most outcomes returned to baseline levels for all three groups. A smaller percentage of participants in OnTrack required chemotherapy dose adjustments than those in the UC or Onco-Move groups (P = .002). Both intervention groups returned earlier (P = .012), as well as for more hours per week (P = .014), to work than the control group.
A supervised, moderate- to high-intensity, combined resistance and aerobic exercise program is most effective for patients with breast cancer undergoing adjuvant chemotherapy. A home-based, low-intensity physical activity program represents a viable alternative for women who are unable or unwilling to follow the higher intensity program.
AuthorsHanna van Waart, Martijn M Stuiver, Wim H van Harten, Edwin Geleijn, Jacobien M Kieffer, Laurien M Buffart, Marianne de Maaker-Berkhof, Epie Boven, Jolanda Schrama, Maud M Geenen, Jetske M Meerum Terwogt, Aart van Bochove, Vera Lustig, Simone M van den Heiligenberg, Carolien H Smorenburg, Jeannette A J H Hellendoorn-van Vreeswijk, Gabe S Sonke, Neil K Aaronson
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 33 Issue 17 Pg. 1918-27 (Jun 10 2015) ISSN: 1527-7755 [Electronic] United States
PMID25918291 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2015 by American Society of Clinical Oncology.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Trastuzumab
  • Activities of Daily Living
  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Chemotherapy, Adjuvant
  • Drug Administration Schedule
  • Exercise
  • Exercise Therapy
  • Fatigue (prevention & control)
  • Female
  • Follow-Up Studies
  • Health Status
  • Humans
  • Middle Aged
  • Motor Activity
  • Muscle Strength
  • Nausea (chemically induced, prevention & control)
  • Pain (etiology, prevention & control)
  • Physical Fitness
  • Quality of Life
  • Self Report
  • Trastuzumab
  • Treatment Outcome
  • Vomiting (chemically induced, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: